Seres Therapeutics, Inc. cash flow to debt ratio of 1.35% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Seres Therapeutics, Inc.'s free cash flow has increased -100.58% from $-148.99M last year to $865.00K, signaling increasing performance

Seres Therapeutics, Inc.'s debt to equity ratio is 3.04, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy

Seres Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 6.65 last year to 3.04 today, signaling strengthened financials

Seres Therapeutics, Inc. has a net debt to EBITDA ratio of 3.78x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk

Seres Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Seres Therapeutics, Inc. has insufficient data to evaluate this check.

Seres Therapeutics, Inc.'s short-term assets of $49.38M exceed its short-term liabilities of $19.32M

Seres Therapeutics, Inc.'s return on assets of -39.87% is lower than the 5.00% threshold, indicating inefficient asset utilization

Seres Therapeutics, Inc.'s return on equity of -127.30%, is lower than 15.00%, indicating bad performance

Seres Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Seres Therapeutics, Inc. had positive net income in only 1.00 out of 5 years, indicating unstable earnings

Seres Therapeutics, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Seres Therapeutics, Inc. has a free cash flow yield of 1.26%, which is below the 2.00% threshold, indicating limited cash return relative to market value

Seres Therapeutics, Inc.'s yearly earnings has increased -103.89% since last year from $-146.57M to $5.70M, signaling increasing performance

Seres Therapeutics, Inc.'s yearly revenue has increased % since last year from $0.00 to $789.00K, signaling increasing performance

ROIC -80.30% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Seres Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Seres Therapeutics, Inc. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance

Seres Therapeutics, Inc. had positive ROE in only 1.00 out of 5 years, indicating inconsistent returns on equity

Seres Therapeutics, Inc. has insufficient data to evaluate this check.

Seres Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Seres Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Seres Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Seres Therapeutics, Inc. has insufficient data to evaluate this check.

Seres Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Seres Therapeutics, Inc. has a price-to-book ratio of 2.56x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Seres Therapeutics, Inc. has a price-to-sales ratio of 59.78x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue